214 related articles for article (PubMed ID: 28279226)
1. The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome.
Huang Y; Powers C; Moore V; Schafer C; Ren M; Phoon CK; James JF; Glukhov AV; Javadov S; Vaz FM; Jefferies JL; Strauss AW; Khuchua Z
Orphanet J Rare Dis; 2017 Mar; 12(1):49. PubMed ID: 28279226
[TBL] [Abstract][Full Text] [Related]
2. The Effects of PPAR Stimulation on Cardiac Metabolic Pathways in Barth Syndrome Mice.
Schafer C; Moore V; Dasgupta N; Javadov S; James JF; Glukhov AI; Strauss AW; Khuchua Z
Front Pharmacol; 2018; 9():318. PubMed ID: 29695963
[No Abstract] [Full Text] [Related]
3. Current and future treatment approaches for Barth syndrome.
Thompson R; Jefferies J; Wang S; Pu WT; Takemoto C; Hornby B; Heyman A; Chin MT; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):17-28. PubMed ID: 34713454
[TBL] [Abstract][Full Text] [Related]
4. A critical appraisal of the tafazzin knockdown mouse model of Barth syndrome: what have we learned about pathogenesis and potential treatments?
Ren M; Miller PC; Schlame M; Phoon CKL
Am J Physiol Heart Circ Physiol; 2019 Dec; 317(6):H1183-H1193. PubMed ID: 31603701
[TBL] [Abstract][Full Text] [Related]
5. Targeted overexpression of catalase to mitochondria does not prevent cardioskeletal myopathy in Barth syndrome.
Johnson JM; Ferrara PJ; Verkerke ARP; Coleman CB; Wentzler EJ; Neufer PD; Kew KA; de Castro Brás LE; Funai K
J Mol Cell Cardiol; 2018 Aug; 121():94-102. PubMed ID: 30008435
[TBL] [Abstract][Full Text] [Related]
6. Cardiolipin Remodeling Defects Impair Mitochondrial Architecture and Function in a Murine Model of Barth Syndrome Cardiomyopathy.
Zhu S; Chen Z; Zhu M; Shen Y; Leon LJ; Chi L; Spinozzi S; Tan C; Gu Y; Nguyen A; Zhou Y; Feng W; Vaz FM; Wang X; Gustafsson AB; Evans SM; Kunfu O; Fang X
Circ Heart Fail; 2021 Jun; 14(6):e008289. PubMed ID: 34129362
[TBL] [Abstract][Full Text] [Related]
7. Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation.
Greenwell AA; Gopal K; Altamimi TR; Saed CT; Wang F; Tabatabaei Dakhili SA; Ho KL; Zhang L; Eaton F; Kruger J; Al Batran R; Lopaschuk GD; Oudit GY; Ussher JR
Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2255-H2269. PubMed ID: 33929899
[TBL] [Abstract][Full Text] [Related]
8. Restoration of mitophagy ameliorates cardiomyopathy in Barth syndrome.
Zhang J; Liu X; Nie J; Shi Y
Autophagy; 2022 Sep; 18(9):2134-2149. PubMed ID: 34985382
[TBL] [Abstract][Full Text] [Related]
9. Cardiolipin remodeling in Barth syndrome and other hereditary cardiomyopathies.
Bertero E; Kutschka I; Maack C; Dudek J
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165803. PubMed ID: 32348916
[TBL] [Abstract][Full Text] [Related]
10. Tafazzin knockdown in mice leads to a developmental cardiomyopathy with early diastolic dysfunction preceding myocardial noncompaction.
Phoon CK; Acehan D; Schlame M; Stokes DL; Edelman-Novemsky I; Yu D; Xu Y; Viswanathan N; Ren M
J Am Heart Assoc; 2012 Apr; 1(2):. PubMed ID: 23130124
[TBL] [Abstract][Full Text] [Related]
11. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
12. Endurance training ameliorates complex 3 deficiency in a mouse model of Barth syndrome.
Soustek MS; Baligand C; Falk DJ; Walter GA; Lewin AS; Byrne BJ
J Inherit Metab Dis; 2015 Sep; 38(5):915-22. PubMed ID: 25860817
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Barth Syndrome by Cardiolipin Manipulation (CARDIOMAN) With Bezafibrate: Protocol for a Randomized Placebo-Controlled Pilot Trial Conducted in the Nationally Commissioned Barth Syndrome Service.
Dabner L; Pieles GE; Steward CG; Hamilton-Shield JP; Ness AR; Rogers CA; Bucciarelli-Ducci C; Greenwood R; Ellis L; Sheehan K; Reeves BC
JMIR Res Protoc; 2021 May; 10(5):e22533. PubMed ID: 34057417
[TBL] [Abstract][Full Text] [Related]
14. Loss of Mitochondrial Ca
Bertero E; Nickel A; Kohlhaas M; Hohl M; Sequeira V; Brune C; Schwemmlein J; Abeßer M; Schuh K; Kutschka I; Carlein C; Münker K; Atighetchi S; Müller A; Kazakov A; Kappl R; von der Malsburg K; van der Laan M; Schiuma AF; Böhm M; Laufs U; Hoth M; Rehling P; Kuhn M; Dudek J; von der Malsburg A; Prates Roma L; Maack C
Circulation; 2021 Nov; 144(21):1694-1713. PubMed ID: 34648376
[TBL] [Abstract][Full Text] [Related]
15. Antioxidant system disturbances and mitochondrial dysfunction induced by 3-methyglutaric acid in rat heart are prevented by bezafibrate.
da Rosa-Junior NT; Parmeggiani B; Glänzel NM; de Moura Alvorcem L; Brondani M; Britto R; Grings M; Ortiz VD; Turck P; da Rosa Araujo AS; Wajner M; Leipnitz G
Eur J Pharmacol; 2022 Jun; 924():174950. PubMed ID: 35430210
[TBL] [Abstract][Full Text] [Related]
16. Cardiolipin deficiency elevates susceptibility to a lipotoxic hypertrophic cardiomyopathy.
Cole LK; Mejia EM; Sparagna GC; Vandel M; Xiang B; Han X; Dedousis N; Kaufman BA; Dolinsky VW; Hatch GM
J Mol Cell Cardiol; 2020 Jul; 144():24-34. PubMed ID: 32418915
[TBL] [Abstract][Full Text] [Related]
17. Long-chain fatty acid oxidation and respiratory complex I deficiencies distinguish Barth Syndrome from idiopathic pediatric cardiomyopathy.
Chatfield KC; Sparagna GC; Specht KS; Whitcomb LA; Omar AK; Miyamoto SD; Wolfe LM; Chicco AJ
J Inherit Metab Dis; 2022 Jan; 45(1):111-124. PubMed ID: 34821394
[TBL] [Abstract][Full Text] [Related]
18. Mitochondria-targeted antioxidant prevents cardiac dysfunction induced by tafazzin gene knockdown in cardiac myocytes.
He Q; Harris N; Ren J; Han X
Oxid Med Cell Longev; 2014; 2014():654198. PubMed ID: 25247053
[TBL] [Abstract][Full Text] [Related]
19. Single Cell Transcriptomic Analysis in a Mouse Model of Barth Syndrome Reveals Cell-Specific Alterations in Gene Expression and Intercellular Communication.
Perera G; Power L; Larson A; Codden CJ; Awata J; Batorsky R; Strathdee D; Chin MT
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511352
[TBL] [Abstract][Full Text] [Related]
20. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Tenenbaum A; Motro M; Fisman EZ
Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
